Gene-expression profiling of adrenocortical carcinoma

References

• Gonzalez RJ, Tamm EP, Ng C et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery142(6), 867–875; discussion 867–875 (2007).
   PubMedGoogle Scholar
• Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg.25(7), 891–897 (2001).
   PubMed Web of Science ®Google Scholar
• Kendrick ML, Lloyd R, Erickson L et al. Adrenocortical carcinoma: surgical progress or status quo? Arch. Surg.136(5), 543–549 (2001).
   PubMedGoogle Scholar
• Paton BL, Novitsky YW, Zerey M et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery140(6), 914–920; discussion 919–920 (2006).
   PubMedGoogle Scholar
• Schteingart DE, Doherty GM, Gauger PG et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr. Relat. Cancer12(3), 667–680 (2005).
   PubMed Web of Science ®Google Scholar
• Sidhu S, Sywak M, Robinson B, Delbridge L. Adrenocortical cancer: recent clinical and molecular advances. Curr. Opin. Oncol.16(1), 13–18 (2004).
   PubMedGoogle Scholar
• Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab.91(6), 2027–2037 (2006).
   PubMed Web of Science ®Google Scholar
• NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”). NIH Consens. State Sci. Statements19(2), 1–25 (2002).
   PubMedGoogle Scholar
• Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J. Surg.30(5), 872–878 (2006).
   PubMed Web of Science ®Google Scholar
• Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med.356(6), 601–610 (2007).
   PubMed Web of Science ®Google Scholar
• Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology222(3), 629–633 (2002).
   PubMed Web of Science ®Google Scholar
• Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev.25(2), 309–340 (2004).
   PubMed Web of Science ®Google Scholar
• Shen WT, Sturgeon C, Duh QY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J. Surg. Oncol.89(3), 186–192 (2005).
   PubMed Web of Science ®Google Scholar
• Sturgeon C, Kebebew E. Laparoscopic adrenalectomy for malignancy. Surg. Clin. North Am.84(3), 755–774 (2004).
   PubMed Web of Science ®Google Scholar
• Sturgeon C, Shen WT, Clark OH, Duh QY, Kebebew E. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J. Am. Coll. Surg.202(3), 423–430 (2006).
   PubMed Web of Science ®Google Scholar
• Lubitz JA, Freeman L, Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA223(10), 1109–1112 (1973).
   PubMed Web of Science ®Google Scholar
• Terzolo M, Angeli A, Fassnacht M et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N. Engl. J. Med.356(23), 2372–2380 (2007).
   PubMed Web of Science ®Google Scholar
• Berruti A, Terzolo M, Sperone P et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr. Relat. Cancer12(3), 657–666 (2005).
   PubMed Web of Science ®Google Scholar
• Khan TS, Imam H, Juhlin C et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann. Oncol.11(10), 1281–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Fareau GG, Lopez A, Stava C, Vassilopoulou-Sellin R. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anticancer Drugs19(6), 637–644 (2008).
   PubMedGoogle Scholar
• Duh QY. Functioning and non-functioning adrenal tumors. In: The Practice of General Surgery. Bland KI (Ed.). WB Saunders, PA, USA, 1077–1082 (2002).
   Google Scholar
• Kebebew E, Siperstein AE, Clark OH, Duh QY. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch. Surg.137(8), 948–951; discussion 952–943 (2002).
   PubMedGoogle Scholar
• Kebebew E, Duh QY. Adrenal incidentaloma. In: Current Surgical Therapy. Cameron JL (Ed.). Elsevier Mosby, PA USA, 575–579 (2004).
   Google Scholar
• Heaston DK, Handel DB, Ashton PR, Korobkin M. Narrow gauge needle aspiration of solid adrenal masses. AJR Am. J. Roentgenol.138(6), 1143–1148 (1982).
   PubMed Web of Science ®Google Scholar
• Berkman WA, Bernardino ME, Sewell CW, Price RB, Sones PJ Jr. The computed tomography-guided adrenal biopsy. An alternative to surgery in adrenal mass diagnosis. Cancer53(10), 2098–2103 (1984).
   PubMedGoogle Scholar
• Katz RL, Patel S, Mackay B, Zornoza J. Fine needle aspiration cytology of the adrenal gland. Acta Cytol.28(3), 269–282 (1984).
   PubMedGoogle Scholar
• Welch TJ, Sheedy PF 2nd, Stephens DH, Johnson CM, Swensen SJ. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology193(2), 341–344 (1994).
   PubMedGoogle Scholar
• Silverman SG, Mueller PR, Pinkney LP, Koenker RM, Seltzer SE. Predictive value of image-guided adrenal biopsy: analysis of results of 101 biopsies. Radiology187(3), 715–718 (1993).
   PubMedGoogle Scholar
• Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol.13(3), 202–206 (1989).
   PubMed Web of Science ®Google Scholar
• Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol.26(12), 1612–1619 (2002).
   PubMed Web of Science ®Google Scholar
• Volante M, Buttigliero C, Greco E, Berruti A, Papotti M. Pathological and molecular features of adrenocortical carcinoma: an update. J. Clin. Pathol.61(7), 787–793 (2008).
   PubMed Web of Science ®Google Scholar
• Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist13(5), 548–561 (2008).
   PubMed Web of Science ®Google Scholar
• Heppner C, Reincke M, Agarwal SK et al.MEN1 gene analysis in sporadic adrenocortical neoplasms. J. Clin. Endocrinol. Metab.84(1), 216–219 (1999).
   PubMed Web of Science ®Google Scholar
• Kjellman M, Roshani L, Teh BT et al. Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. J. Clin. Endocrinol. Metab.84(2), 730–735 (1999).
   PubMedGoogle Scholar
• Schulte KM, Mengel M, Heinze M et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. J. Clin. Endocrinol. Metab.85(1), 441–448 (2000).
   PubMedGoogle Scholar
• Wachenfeld C, Beuschlein F, Zwermann O et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol.145(3), 335–341 (2001).
   PubMed Web of Science ®Google Scholar
• Sidhu S, Marsh DJ, Theodosopoulos G et al. Comparative genomic hybridization analysis of adrenocortical tumors. J. Clin. Endocrinol. Metab.87(7), 3467–3474 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao J, Speel EJ, Muletta-Feurer S et al. Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. Am. J. Pathol.155(4), 1039–1045 (1999).
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Thomas DG, Kuick R et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol.162(2), 521–531 (2003).
   PubMed Web of Science ®Google Scholar
• de Fraipont F, El Atifi M, Cherradi N et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab.90(3), 1819–1829 (2005).
   PubMed Web of Science ®Google Scholar
• Velazquez-Fernandez D, Laurell C, Geli J et al. Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. Surgery138(6), 1087–1094 (2005).
   PubMed Web of Science ®Google Scholar
• Slater EP, Diehl SM, Langer P et al. Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur. J. Endocrinol.154(4), 587–598 (2006).
   PubMed Web of Science ®Google Scholar
• Lombardi CP, Raffaelli M, Pani G et al. Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study. Biomed. Pharmacother.60(4), 186–190 (2006).
   PubMedGoogle Scholar
• West AN, Neale GA, Pounds S et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res.67(2), 600–608 (2007).
   PubMedGoogle Scholar
• Fernandez-Ranvier GG, Weng J, Yeh RF et al. Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. Arch. Surg.143(9), 841–846; discussion 846 (2008).
   PubMedGoogle Scholar
• Rogers S, Cambrosio A. Making a new technology work: the standardization and regulation of microarrays. Yale J. Biol. Med.80(4), 165–178 (2007).
   PubMedGoogle Scholar
• Steinhoff C, Vingron M. Normalization and quantification of differential expression in gene expression microarrays. Brief Bioinform.7(2), 166–177 (2006).
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer4(7), 505–518 (2004).
   PubMed Web of Science ®Google Scholar
• Gicquel C, Bertagna X, Schneid H et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab.78(6), 1444–1453 (1994).
   PubMed Web of Science ®Google Scholar
• Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res.61(18), 6762–6767 (2001).
   PubMed Web of Science ®Google Scholar
• Almeida MQ, Fragoso MC, Lotfi CF et al. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J. Clin. Endocrinol. Metab.93(9), 3524–3531 (2008).
   PubMed Web of Science ®Google Scholar
• Barlaskar FM, Spalding AC, Heaton JH et al. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab.94(1), 204–212 (2009).
   PubMed Web of Science ®Google Scholar
• Schmitt A, Saremaslani P, Schmid S et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology49(3), 298–307 (2006).
   PubMed Web of Science ®Google Scholar
• Fernandez-Ranvier GG, Weng J, Yeh RF et al. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J. Surg.32(5), 873–881 (2008).
   PubMed Web of Science ®Google Scholar
• de Reynies A, Assie G, Rickman DS et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol.27(7), 1108–1115 (2009).
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Kuick R, Else T et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res.15(2), 668–676 (2009).
   PubMed Web of Science ®Google Scholar